CLINICAL_TRIALS
trial_result
· 2020-02-11
Clinical Trial Update: Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients [Phase 2]
Summary
Phase 2 clinical trial update on AFQ056 for Fragile X Syndrome evaluating efficacy, safety, and tolerability.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED